Product
Psilocybin
Aliases
4-phosphoryloxy-N,N-dimethyltryptamine, COMP360, CY-39, Indocybin, Low Dose Psilocybin (10 other aliases)
115 clinical trials
113 indications
Indication
AnorexiaIndication
Post-Traumatic Stress DisorderIndication
DepressionIndication
Fragile X SyndromeIndication
BehaviourIndication
Cognitive ImpairmentIndication
Major Depressive DisorderIndication
Treatment Resistant DisordersIndication
Alcohol Use DisorderIndication
Mood DisorderIndication
Sleep DisturbanceIndication
Drug EffectIndication
healthIndication
SubjectiveIndication
Psilocin ToxicityIndication
Psilocybin PoisoningIndication
PsilocybinIndication
AnxietyIndication
Hematopoietic and Lymphoid Cell NeoplasmIndication
Malignant Solid NeoplasmIndication
Obsessive-Compulsive DisorderIndication
MigraineIndication
Phantom Limb PainIndication
HealthyIndication
InsomniaIndication
Nicotine DependenceIndication
Pancreatic CancerIndication
Bile Duct CancerIndication
Psychological DistressIndication
FibromyalgiaIndication
Severe Alcohol Use DisorderIndication
Mild Cognitive ImpairmentIndication
Low Back PainIndication
Distorted PerceptionIndication
Visual SuppressionIndication
Suicidal IdeationIndication
Cluster HeadacheIndication
Mood DisordersIndication
AgingIndication
Mental HealthIndication
Alcohol use disorderIndication
Tobacco Use DisorderIndication
PTSDIndication
Chronic PTSDIndication
Perception DisordersIndication
Opioid Use DisorderIndication
End-of-life careIndication
DemoralizationIndication
Terminal IllnessIndication
Cancer-related Problem/ConditionIndication
psychotherapyIndication
Terminal CancerIndication
CancerIndication
Advanced CancerIndication
Cannabis Use DisorderIndication
ModerateIndication
SevereIndication
Opioid DependenceIndication
Chronic PainIndication
Stress DisordersIndication
AnhedoniaIndication
TraumaIndication
Post-TraumaticIndication
Trauma- and Stressor-Related DisordersIndication
Mental IllnessIndication
Breast CancerIndication
Ovarian CancerIndication
DistressIndication
EmotionalIndication
Recurrent Depressive DisorderIndication
Post-Traumatic HeadacheIndication
Autism Spectrum DisorderIndication
Alcohol-Related DisordersIndication
Substance Use DisorderIndication
Healthy Control ParticipantsIndication
MajorIndication
Methamphetamine Use DisorderIndication
Substance-Related DisordersIndication
Chemically Induced DisordersIndication
Substance Use DisordersIndication
Stimulant Use DisorderIndication
Alzheimer's diseaseIndication
Opioid-Related DisordersIndication
Pain ManagementIndication
Pain Management and CareIndication
Advanced CancersIndication
SafetyIndication
FeasibilityIndication
Psilocybin Treatment in Individuals With Functional Impairment Due to Psychiatric SymptomsIndication
Metastatic Malignant Solid NeoplasmIndication
QTc IntervalIndication
pharmacokineticsIndication
Post-Treatment Lyme DiseaseIndication
Lyme DiseaseIndication
ChronicIndication
PrimaryIndication
NeuroimagingIndication
Vagus Nerve StimulationIndication
Bipolar II DisorderIndication
BurnoutIndication
CaregiverIndication
OccupationalIndication
COVID-19Indication
Moral InjuryIndication
Body Dysmorphic DisorderIndication
Cocaine-Related DisordersIndication
Parkinson's diseaseIndication
borderline personality disorderIndication
Alcohol abuseIndication
Cocaine use disorderClinical trial
Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept StudyStatus: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress DisorderStatus: Active (not recruiting), Estimated PCD: 2023-12-19
Clinical trial
A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant DepressionStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant DepressionStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
An Open-Label Investigation of the Effects of Sub-Perceptual Repeat Dosing of Psilocybin on the Behavioural and Cognitive Symptoms of Fragile X Syndrome in Adult PatientsStatus: , Estimated PCD: 2024-05-01
Clinical trial
A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive DisorderStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant DepressionStatus: Completed, Estimated PCD: 2021-07-30
Clinical trial
A 24-Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Clinical Trial to Evaluate Efficacy and Safety of Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)Status: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress DisorderStatus: Active (not recruiting), Estimated PCD: 2023-10-30
Clinical trial
Evaluating the Effect of Length of Time on Selective Serotonin Reuptake Inhibitors (SSRIs) on the Response to Psilocybin-assisted Therapy in Individuals With Mild-moderate Major Depressive Disorder (MDD)Status: Withdrawn, Estimated PCD: 2023-03-14
Clinical trial
The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant DepressionStatus: Completed, Estimated PCD: 2021-10-14
Clinical trial
Mood and Cognitive Effects of Low Doses of Psilocybin Observed in Healthy Subjects ("MELO"): A Blinded, Placebo-Controlled, Dose-Finding StudyStatus: Withdrawn, Estimated PCD: 2023-08-01
Clinical trial
An Exploratory Open-Label, Phase 1b, Ascending Dose Study to Evaluate the Effects of Oral 3-[2-(Dimethylamino)Ethyl]-1h-indol-4-yl Dihydrogen Phosphate (Psilocybin, BPL-PSILO) on Cognition in Patients With Chronic Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)Status: Terminated, Estimated PCD: 2022-04-22
Clinical trial
The Safety, Feasibility, and Acceptability of Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain (P-PC)Status: Active (not recruiting), Estimated PCD: 2024-08-31
Clinical trial
PsilOCD: Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity (A Pharmacological-Challenge Feasibility Study)Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDDStatus: Withdrawn, Estimated PCD: 2023-06-01
Clinical trial
Repeat Dosing of Psilocybin in Headache DisordersStatus: Completed, Estimated PCD: 2023-11-05
Clinical trial
Behavioral and Neural Mechanisms Supporting Psilocybin-assisted Therapy for Phantom Limb PainStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Multi-centre, Double-blinded, Placebo-controlled, Randomised, Phase II Clinical Trial for Psilocybin-assisted Therapy for Alcohol Use DisorderStatus: Not yet recruiting, Estimated PCD: 2025-07-01
Clinical trial
Consciousness and Psilocybin Effects on Well-Being (The CoPE Study): Pilot PhaseStatus: , Estimated PCD: 2025-06-01
Clinical trial
Safety for Home Administration of Microdose Psilocybin UseStatus: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
Psilocybin-facilitated Smoking Cessation Treatment: A Pilot StudyStatus: Completed, Estimated PCD: 2023-05-01
Clinical trial
An Exploratory Pilot Study of Palliadelic Treatment to Reduce Psychological Distress and Improve Quality of Life in Persons With Pancreatobiliary Cancer, With a Parallel Assessment of Healthcare Utilization and Family WellbeingStatus: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Phase II Randomized, Double-blind, Active Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of Psilocybin in Treatment-resistant Major DepressionStatus: Active (not recruiting), Estimated PCD: 2024-03-01
Clinical trial
A Phase 2a, Open-label, Pilot Study to Assess the Safety and Efficacy of Psilocybin Administration in Concert With Psychotherapy Among Adult Patients With FibromyalgiaStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Feasibility, Clinical Efficacy & (Neuro)Cognitive MechanismsStatus: Not yet recruiting, Estimated PCD: 2025-12-15
Clinical trial
Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for Alcohol Use DisorderStatus: Not yet recruiting, Estimated PCD: 2029-01-01
Clinical trial
Does Psilocybin Change Synaptic Density in the Brains of Patients With Amnestic Mild Cognitive ImpairmentStatus: Recruiting, Estimated PCD: 2026-07-01
Clinical trial
Psilocybin and Affective Function in Chronic Lower Back Pain DepressionStatus: Recruiting, Estimated PCD: 2026-07-30
Clinical trial
Visual Surround Suppression and Perceptual Expectation Under PsilocybinStatus: Terminated, Estimated PCD: 2023-09-01
Clinical trial
The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal IdeationStatus: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy SubjectsStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Effects and Therapeutic Potential of Psilocybin in Alcohol DependenceStatus: Completed, Estimated PCD: 2013-09-01
Clinical trial
Phase II, Randomized, Double Blind, Placebo Controlled, Parallel Group, Single Center Study of Psilocybin Efficacy and Mechanism in Alcohol Use DisorderStatus: Completed, Estimated PCD: 2023-03-14
Clinical trial
Psilocybin-assisted Psychotherapy in the Treatment of Patients Hospitalized for Treatment-resistant Depression: an Open-label Feasibility Study With an Experiential and Systemic FocusStatus: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
Safety and Efficacy of Psilocybin for the Treatment of Headache DisordersStatus: Completed, Estimated PCD: 2022-06-30
Clinical trial
Engaging Mood Brain Circuits With Psilocybin: a Randomized Neuroimaging Trial in DepressionStatus: Not yet recruiting, Estimated PCD: 2027-08-01
Clinical trial
Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: A Randomized Phase II Clinical Trial Comparing One Versus Two Psychedelic Doses of Psilocybin (PSI-1V2)Status: Recruiting, Estimated PCD: 2028-02-01
Clinical trial
Psilocybin in Patients With Fibromyalgia: EEG-measured Brain Biomarkers of ActionStatus: Active (not recruiting), Estimated PCD: 2024-01-10
Clinical trial
Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older AdultsStatus: Not yet recruiting, Estimated PCD: 2026-12-30
Clinical trial
A Pilot Study of Feasibility, Efficacy, and Mechanisms of Mindfulness-assisted Psychedelic TherapyStatus: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
Mechanisms Supporting Psilocybin-assisted Psychotherapy for Alcohol Use Disorder: A Randomized, Controlled Clinical TrialStatus: Recruiting, Estimated PCD: 2027-10-01
Clinical trial
5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use DisorderStatus: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
Does Serotonin System Stimulation Increase Pro-social Behavior? - A Comparative Pharmacological Neuroscientific Study in Healthy HumansStatus: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
Psilocybin-Assisted Massed Cognitive Processing Therapy for Chronic Posttraumatic Stress Disorder: An Open-label TrialStatus: Not yet recruiting, Estimated PCD: 2025-03-01
Clinical trial
Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the BrainStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Phase I Study of the Safety and Adjunctive Effects of Psilocybin in Adults With Opioid Use Disorder Maintained on a Buprenorphine/Naloxone FormulationStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care - PATH StudyStatus: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
Safety and Tolerability of Psilocybin in Post-Traumatic Stress DisorderStatus: Withdrawn, Estimated PCD: 2025-12-01
Clinical trial
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Psilocybin-assisted Psychotherapy on Psychiatric and Existential Distress in Advanced CancerStatus: Recruiting, Estimated PCD: 2027-01-01
Clinical trial
Effects of Psilocybin in Advanced-Stage Cancer Patients With AnxietyStatus: Completed, Estimated PCD: 2008-12-01
Clinical trial
A Randomized, Double-Blind Study of Psilocybin for Opioid Use Disorder in Patients on Methadone Maintenance With Ongoing Opioid UseStatus: Withdrawn, Estimated PCD: 2024-02-01
Clinical trial
The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density - A Single Dose Randomized, Double Blind, Placebo- Controlled Phase 2 Positron Emission Tomography StudyStatus: Completed, Estimated PCD: 2023-04-19
Clinical trial
Effects of Psilocybin on Electrophysiology and the Dynamic Content of ThoughtStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Pragmatic Trial of Psilocybin Therapy in Palliative Care (PT2PC): A Multicenter Triple-blind Phase 2 Randomized Controlled Trial of Psilocybin Therapy for Demoralized Adults Near the End of LifeStatus: Not yet recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Double-blind, Randomized Trial Examining the Preliminary Efficacy of Psilocybin Therapy for People With Chronic Low Back PainStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Does Psilocybin Require Psychedelic Effects to Treat Depression? A 4-Week, Double-Blind, Proof-of-Concept Randomized Controlled TrialStatus: Recruiting, Estimated PCD: 2026-02-01
Clinical trial
A 9-week Phase 2 Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Psilocybin-assisted-psychotherapy in Adults With Cannabis Use Disorder: A Proof-of-Concept StudyStatus: Not yet recruiting, Estimated PCD: 2026-03-01
Clinical trial
The Impact of Psilocybin on Pain in Fibromyalgia Patients: a Multicentre Trial.Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication in Patients With Chronic Pain: an Open-label Feasibility StudyStatus: Not yet recruiting, Estimated PCD: 2025-02-28
Clinical trial
Examining the Safety and Clinical Efficacy of Psilocybin Therapy for Veterans With PTSD: An Open-Label Proof-of-Concept TrialStatus: Recruiting, Estimated PCD: 2025-01-31
Clinical trial
Effects of Psilocybin With Psychological Support on Anhedonia in Treatment-resistant Depression: a Randomized Controlled Pilot TrialStatus: Not yet recruiting, Estimated PCD: 2025-03-01
Clinical trial
Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive DisorderStatus: Active (not recruiting), Estimated PCD: 2021-07-08
Clinical trial
Exploratory Study of the Effects of Low-Dose Psilocybin on Sensory Processing, Neurophysiological Arousal, and Emotional HealthStatus: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
A Phase 1b Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence in Patients Diagnosed With Early-stage Breast Cancer and Ovarian Cancer in RemissionStatus: Not yet recruiting, Estimated PCD: 2026-12-01
Clinical trial
PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site, Open-label, Single Arm Phase I/II Proof-of-concept, Dose-finding, and Feasibility Clinical TrialStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Comparison of the Effects of PEX20 (Oral Psilocin), PEX30 (Sublingual Psilocin), and PEX10 (Oral Psilocybin) in Healthy AdultsStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
The QUANTUM Trip Trial - Psilocybin-assisted Therapy for Reducing Alcohol Intake in Patients With Alcohol Use Disorder: A Randomized, Double-blinded, Placebo-controlled Clinical Trial.Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
Assessing the Safety, Tolerability, and Efficacy of Psilocybin Therapy Followed by Accelerated Intermittent Theta Burst (aiTBS) Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment-Resistant Major Depressive DisorderStatus: Not yet recruiting, Estimated PCD: 2027-03-15
Clinical trial
Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders: Sub-Study IIStatus: Terminated, Estimated PCD: 2023-06-27
Clinical trial
Modulation of Serotonin Pathways Using Psilocybin in Adults With and Without Autism Spectrum Disorder (ASD)Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
Study of Psilocybin for Anorexia in Young AdultsStatus: Not yet recruiting, Estimated PCD: 2029-06-01
Clinical trial
Psilocybin in Alcohol Use Disorder With Comorbid DepressionStatus: Not yet recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 (Psilocybin) in Healthy ParticipantsStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Low-Income Group Psilocybin Assisted Therapy for Depression: A Feasibility StudyStatus: Not yet recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD)Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
Safety and Feasibility of Psilocybin in Methamphetamine Use Disorder in a Community-Based SampleStatus: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
Psilocybin for Treatment of Alcohol Use Disorder: a Feasibility StudyStatus: Active (not recruiting), Estimated PCD: 2024-06-21
Clinical trial
Psilocybin-assisted Cognitive Behavioral Therapy for DepressionStatus: , Estimated PCD: 2025-06-01
Clinical trial
CAPSI - Cancer Related Major Depression Treated With a Single Dose of Psilocybin: A Multicenter Randomized Placebo Controlled Double Blind Clinical TrialStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Pilot Study of Serotonin 2A Receptor (5-HT2A) Agonist Psilocybin for Depression in Patients With Mild Cognitive Impairment or Early Alzheimer's DiseaseStatus: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients With Advanced CancerStatus: Not yet recruiting, Estimated PCD: 2025-12-31
Clinical trial
Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept StudyStatus: Not yet recruiting, Estimated PCD: 2027-07-01
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of up to Two Doses of Psilocybin for the Treatment of Major Depressive Disorder in Adults With CancerStatus: Recruiting, Estimated PCD: 2025-08-31
Clinical trial
Evaluation of the Acceptability, Safety, Feasibility, and Efficacy of Psilocybin-assisted Psychotherapy (PaP) for the Treatment of Post-traumatic Stress Disorder (PTSD) in Military VeteransStatus: Not yet recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Phase 1/2 Study of a Group Model of Psilocybin-Assisted Therapy for Cancer-Related Anxiety in Patients With Metastatic CancerStatus: Active (not recruiting), Estimated PCD: 2024-04-08
Clinical trial
Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use DisorderStatus: Recruiting, Estimated PCD: 2025-08-31
Clinical trial
A Phase 1, Two-Part Study in Healthy Volunteers to Evaluate The Effect of Psilocybin on Cardiac Repolarization and The Effect of Food on Psilocybin PharmacokineticsStatus: Completed, Estimated PCD: 2023-08-09
Clinical trial
The Efficacy and Tolerability of Psilocybin in Participants With Treatment-Resistant Depression: a Phase 2, Randomized Feasibility StudyStatus: Completed, Estimated PCD: 2023-07-22
Clinical trial
Effects of Psilocybin in Post-Treatment Lyme DiseaseStatus: , Estimated PCD: 2024-09-30
Clinical trial
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive DisorderStatus: Not yet recruiting, Estimated PCD: 2026-06-30
Clinical trial
Psilocybin-Assisted vs Ketamine-Assisted Psychotherapy for Alcohol Use DisorderStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Effects of Psilocybin-facilitated Experience on the Psychology and Effectiveness of Professional Leaders in ReligionStatus: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
Psilocybin-facilitated Treatment for Chronic PainStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Multivariate Neural and Physiological Correlates of Psychedelic Sub-states: a Within-subjects, Healthy Volunteer Study With Experience-samplingStatus: Recruiting, Estimated PCD: 2025-11-30
Clinical trial
Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind TrialStatus: , Estimated PCD: 2028-07-01
Clinical trial
Activating Neuroplasticity to ENHANCE the Perception Box Expanding Effects of PsilocybinStatus: Not yet recruiting, Estimated PCD: 2027-07-01
Clinical trial
An Open-Label Pilot Study Examining the Feasibility, Safety, and Effectiveness of Psilocybin Therapy for Depression in Bipolar II DisorderStatus: Recruiting, Estimated PCD: 2024-01-01
Clinical trial
Evaluating the Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant Obsessive-compulsive Disorder: An Open-label Clinical TrialStatus: Not yet recruiting, Estimated PCD: 2024-06-01
Clinical trial
Psilocybin as a Treatment for Anorexia Nervosa: A Pilot StudyStatus: Active (not recruiting), Estimated PCD: 2023-06-01
Clinical trial
A Randomized, Placebo-controlled Trial of Psychedelic-assisted Psychotherapy With Single Dose Psilocybin for Frontline Clinicians Experiencing COVID-related Symptoms of Depression and BurnoutStatus: Active (not recruiting), Estimated PCD: 2024-03-30
Clinical trial
Safety and Efficacy of Psilocybin for Body Dysmorphic DisorderStatus: Completed, Estimated PCD: 2022-11-02
Clinical trial
Psilocybin-facilitated Treatment for Cocaine Use: A Pilot StudyStatus: Completed, Estimated PCD: 2024-05-01
Clinical trial
Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: a Pilot StudyStatus: Completed, Estimated PCD: 2023-06-13
Clinical trial
Comparative Acute Effects of LSD, Psilocybin and Mescaline in a Random-Order Placebo-Controlled Cross-Over Study in Healthy SubjectsStatus: Completed, Estimated PCD: 2022-09-02
Clinical trial
An Open Label Study of Single-Dose Psilocybin for Major Depressive Disorder With Co-occurring Borderline Personality DisorderStatus: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
SV2A Marker of Synaptogenesis in a Clinical Trial of Psilocybin for DepressionStatus: Withdrawn, Estimated PCD: 2025-01-01
Clinical trial
A Randomized, Double-Blind, Support-of-Concept Phase 2 Study of Single-Dose Psilocybin for Major Depressive Disorder (MDD)Status: Completed, Estimated PCD: 2022-06-28
Clinical trial
Psilocybin for the Treatment of Major Depressive DisorderStatus: Not yet recruiting, Estimated PCD: 2025-01-01
Clinical trial
Psilocybin vs Ketamine for Alcohol Use DisorderStatus: Not yet recruiting, Estimated PCD: 2027-06-01
Clinical trial
A Phase 1 Study Comparing the Pharmacokinetics and Safety of Intravenous and Oral PsilocybinStatus: Withdrawn, Estimated PCD: 2024-03-01
Clinical trial
Effects of Psilocybin in Obsessive Compulsive DisorderStatus: Recruiting, Estimated PCD: 2025-09-12
Clinical trial
Safety Profile of 25 mg Psilocybin in Individuals With Cocaine Use DisorderStatus: Not yet recruiting, Estimated PCD: 2025-12-01